Original from: 360dx

Akoya Biosciences on Tuesday said it has inked an exclusive global license agreement with German molecular diagnostics firm NeraCare to develop and commercialize NeraCare’s Immunoprint test for early-stage melanoma on Akoya's immunofluorescence platform.

The agreement, financial terms of which were not announced, builds on an existing research collaboration between the companies that was announced in May.

Under the deal, Marlborough, Massachusetts-based Akoya obtained the exclusive right to develop, market, and commercialize the Immunoprint test for clinical research, diagnostic development, or, following regulatory approval, patient clinical testing.

The company plans to develop the assay into both a laboratory test and a distributable diagnostic on Akoya's PhenoImager HT platform for the prognosis of disease recurrence and therapy guidance in early-stage melanoma patients.

"The agreement builds on the complementary expertise of both companies: Akoya’s market-leading multiplex immunofluorescence technology and NeraCare’s innovative development and rigorous clinical validation of Immunoprint," NeraCare Cofounder Friedrich Ackermann said in a statement. "Together, we aim to expand access to life-saving therapies for early-stage melanoma patients worldwide."

"Our exclusive partnership with NeraCare for Immunoprint is a significant advancement of our clinical strategy providing Akoya and our pharmaceutical partners the opportunity to transform melanoma patient care," Akoya CEO Brian McKelligon added.

Source: Akoya Biosciences Licenses Early-Stage Melanoma Test From NeraCare